Bulletin
Investor Alert

Repligen Corp.

NAS: RGEN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 2, 2020, 5:18 p.m.

/zigman2/quotes/210324360/composite

$

126.80

Change

+0.15 +0.12%

Volume

Volume 3,563

Quotes are delayed by 20 min

/zigman2/quotes/210324360/composite

Previous close

$ 124.19

$ 126.65

Change

+2.46 +1.98%

Day low

Day high

$124.32

$127.64

Open

52 week low

52 week high

$72.32

$143.93

Open

Company Description

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products u...

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Valuation

P/E Current

291.06

P/E Ratio (with extraordinary items)

290.26

P/E Ratio (without extraordinary items)

212.60

Price to Sales Ratio

16.84

Price to Book Ratio

4.55

Price to Cash Flow Ratio

73.69

Enterprise Value to EBITDA

100.93

Enterprise Value to Sales

21.53

Total Debt to Enterprise Value

0.06

Efficiency

Revenue/Employee

355,118.00

Income Per Employee

28,135.00

Receivables Turnover

6.81

Total Asset Turnover

0.25

Liquidity

Current Ratio

13.28

Quick Ratio

12.15

Cash Ratio

11.12

Profitability

Gross Margin

51.15

Operating Margin

14.83

Pretax Margin

9.68

Net Margin

7.92

Return on Assets

1.97

Return on Equity

2.56

Return on Total Capital

3.93

Return on Invested Capital

2.21

Capital Structure

Total Debt to Total Equity

24.85

Total Debt to Total Capital

19.90

Total Debt to Total Assets

18.81

Long-Term Debt to Equity

24.51

Long-Term Debt to Total Capital

19.63

Officers and Executives

Name Age Officer Since Title
Mr. Tony J. Hunt 55 2014 President, Chief Executive Officer & Director
Mr. Steve Curran - 2015 Vice President-Global Operations
Mr. Jon K. Snodgres 53 2014 Secretary, Chief Financial & Accounting Officer
Mr. Ralf Kuriyel 60 2016 Senior Vice President-Research & Development
Mr. Vikas Gupta - 2016 Vice President-Strategy Growth Initiatives

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/18/2020 Karen A. Dawes
Director
2,568   Disposition at $116.56 per share. 299,326
06/18/2020 Karen A. Dawes
Director
8,217   Disposition at $115.76 per share. 951,199
06/18/2020 Karen A. Dawes
Director
5,243   Disposition at $114.49 per share. 600,271
06/18/2020 Karen A. Dawes
Director
2,677   Disposition at $113.58 per share. 304,053
05/21/2020 Tony J. Hunt
Chief Executive Officer; Director
3,086   Derivative/Non-derivative trans. at $32.4 per share. 99,986
05/21/2020 Tony J. Hunt
Chief Executive Officer; Director
39,037   Derivative/Non-derivative trans. at $24.98 per share. 975,144
05/21/2020 Tony J. Hunt
Chief Executive Officer; Director
7,916   Derivative/Non-derivative trans. at $16.55 per share. 131,009
05/21/2020 Tony J. Hunt
Chief Executive Officer; Director
100   Disposition at $141.58 per share. 14,158
05/21/2020 Tony J. Hunt
Chief Executive Officer; Director
1,377   Disposition at $140.99 per share. 194,143
05/21/2020 Tony J. Hunt
Chief Executive Officer; Director
28,980   Disposition at $140.04 per share. 4,058,359
05/21/2020 Tony J. Hunt
Chief Executive Officer; Director
16,496   Disposition at $139.17 per share. 2,295,748
05/20/2020 Karen A. Dawes
Director
182   Disposition at $140.29 per share. 25,532
05/20/2020 Karen A. Dawes
Director
282   Disposition at $139.4 per share. 39,310
05/20/2020 Karen A. Dawes
Director
43   Disposition at $136.98 per share. 5,890
05/20/2020 Karen A. Dawes
Director
10   Disposition at $135.91 per share. 1,359
05/18/2020 Karen A. Dawes
Director
80   Disposition at $142.45 per share. 11,396
05/18/2020 Karen A. Dawes
Director
77   Disposition at $141.45 per share. 10,891
05/18/2020 Karen A. Dawes
Director
180   Disposition at $140.62 per share. 25,311
05/18/2020 Karen A. Dawes
Director
122   Disposition at $139.32 per share. 16,997
05/18/2020 Karen A. Dawes
Director
269   Disposition at $138.6 per share. 37,283
05/18/2020 Karen A. Dawes
Director
160   Disposition at $136.92 per share. 21,907
05/18/2020 Karen A. Dawes
Director
712   Disposition at $135.76 per share. 96,661
05/18/2020 Karen A. Dawes
Director
80   Disposition at $142.45 per share. 11,396
05/18/2020 Karen A. Dawes
Director
77   Disposition at $141.45 per share. 10,891
05/18/2020 Karen A. Dawes
Director
180   Disposition at $140.62 per share. 25,311
05/18/2020 Karen A. Dawes
Director
122   Disposition at $139.32 per share. 16,997
05/18/2020 Karen A. Dawes
Director
269   Disposition at $138.6 per share. 37,283
05/18/2020 Karen A. Dawes
Director
160   Disposition at $136.92 per share. 21,907
05/18/2020 Karen A. Dawes
Director
712   Disposition at $135.76 per share. 96,661
05/18/2020 Nicolas M. Barthelemy
Director
3,009   Disposition at $142.53 per share. 428,872
05/18/2020 Nicolas M. Barthelemy
Director
2,109   Derivative/Non-derivative trans. at $67.71 per share. 142,800
05/15/2020 Jon K. Snodgres
Chief Financial Officer
660   Disposition at $140.43 per share. 92,683
05/15/2020 Ralf Kuriyel
Senior VP, R&D
435   Disposition at $140.69 per share. 61,200
05/13/2020 Karen A. Dawes
Director
722   Award at $0 per share. 0
05/13/2020 Karen A. Dawes
Director
722   Award at $0 per share. 0
05/13/2020 Glenn P. Muir
Director
527   Award at $0 per share. 0
05/13/2020 Nicolas M. Barthelemy
Director
527   Award at $0 per share. 0
05/13/2020 Thomas F. Ryan
Director
527   Award at $0 per share. 0
05/13/2020 Jon K. Snodgres
Chief Financial Officer
9,024   Derivative/Non-derivative trans. at $32.4 per share. 292,377
05/13/2020 Jon K. Snodgres
Chief Financial Officer
3,170   Derivative/Non-derivative trans. at $26.05 per share. 82,578
05/13/2020 Ralf Kuriyel
Senior VP, R&D
2,000   Derivative/Non-derivative trans. at $33.87 per share. 67,740
05/13/2020 Ralf Kuriyel
Senior VP, R&D
6,000   Derivative/Non-derivative trans. at $33.05 per share. 198,300
05/13/2020 Jon K. Snodgres
Chief Financial Officer
846   Disposition at $132.37 per share. 111,985
05/13/2020 Jon K. Snodgres
Chief Financial Officer
3,013   Disposition at $131.38 per share. 395,847
05/13/2020 Jon K. Snodgres
Chief Financial Officer
1,700   Disposition at $130.2 per share. 221,340
05/13/2020 Jon K. Snodgres
Chief Financial Officer
1,612   Disposition at $128.7 per share. 207,464
05/13/2020 Jon K. Snodgres
Chief Financial Officer
2,865   Disposition at $127.75 per share. 366,003
05/13/2020 Jon K. Snodgres
Chief Financial Officer
5,358   Disposition at $126.77 per share. 679,233
05/13/2020 Ralf Kuriyel
Senior VP, R&D
95   Disposition at $128.55 per share. 12,212
05/13/2020 Ralf Kuriyel
Senior VP, R&D
6,293   Disposition at $128.02 per share. 805,629
05/13/2020 Ralf Kuriyel
Senior VP, R&D
1,612   Disposition at $126.88 per share. 204,530
04/22/2020 Nicolas M. Barthelemy
Director
2,688   Disposition at $109.99 per share. 295,653
04/22/2020 Nicolas M. Barthelemy
Director
1,652   Derivative/Non-derivative trans. at $42.07 per share. 69,499
04/21/2020 Karen A. Dawes
Director
11,800   Derivative/Non-derivative trans. at $3.3 per share. 38,940
04/21/2020 Karen A. Dawes
Director
11,800   Derivative/Non-derivative trans. at $3.3 per share. 38,940
04/20/2020 Karen A. Dawes
Director
8,998   Disposition at $104.42 per share. 939,571
04/20/2020 Karen A. Dawes
Director
3,202   Disposition at $104.98 per share. 336,145
04/20/2020 Karen A. Dawes
Director
8,998   Disposition at $104.42 per share. 939,571
04/20/2020 Karen A. Dawes
Director
3,202   Disposition at $104.98 per share. 336,145
04/20/2020 Karen A. Dawes
Director
8,200   Derivative/Non-derivative trans. at $3.3 per share. 27,060
04/20/2020 Karen A. Dawes
Director
8,200   Derivative/Non-derivative trans. at $3.3 per share. 27,060
04/03/2020 Nicolas M. Barthelemy
Director
2,688   Disposition at $99.99 per share. 268,773
04/03/2020 Nicolas M. Barthelemy
Director
1,652   Derivative/Non-derivative trans. at $42.07 per share. 69,499
/news/latest/company/us/rgen

MarketWatch News on RGEN

  1. Small-Cap ‘Darlings’ Are Perking Up in 2020

    11:47 a.m. Jan. 21, 2020

    - Barron's Online

  2. These 6 stocks in the S&P 1500 have more than doubled in 12 months

    7:28 a.m. July 13, 2019

    - Philip van Doorn

  3. Repligen started at overweight with $42 stock price target at J.P. Morgan

    8:28 a.m. Dec. 5, 2017

    - Tomi Kilgore

  4. Repligen stock fair value estimate raised to $47 from $42 at Janney

    11:26 a.m. June 23, 2017

    - Tomi Kilgore

  5. Repligen agrees to buy Spectrum in a cash-and-stock deal valued at $359 mln

    7:01 a.m. June 23, 2017

    - Tomi Kilgore

  6. Repligen's stock halted for news pending

    6:58 a.m. June 23, 2017

    - Tomi Kilgore

  7. Repligen's stock was inactive premarket prior to trading halt

    6:59 a.m. June 23, 2017

    - Tomi Kilgore

  8. Investing From the Ground Up

    12:13 a.m. Sept. 15, 2016

    - Barron's Online

  9. Why Danaher’s Purchase of Pall Means More M&A is on the Way

    11:39 a.m. May 13, 2015

    - Barrons Blogs

  10. Bull trend absorbs soft second-quarter start

    10:41 a.m. April 6, 2015

    - Michael Ashbaugh

  11. These are the most profitable Nasdaq biotech companies

    12:36 p.m. March 2, 2015

    - Philip van Doorn

  12. Here are the best-performing stocks so far in 2015

    12:47 p.m. Jan. 9, 2015

    - Philip van Doorn

  13. 13D Filings

    7:45 a.m. July 27, 2013

    - Barron's Online

  14. 13D Filings

    4:25 a.m. July 20, 2013

    - Barron's Online

  15. Loading more headlines...
/news/nonmarketwatch/company/us/rgen

Other News on RGEN

  1. LGND or RGEN: Which Is the Better Value Stock Right Now?

    11:40 a.m. Today

    - Zacks.com

  2. Repligen to buy engineered molding technology firm

    12:15 p.m. June 29, 2020

    - Seeking Alpha

  3. LGND or RGEN: Which Is the Better Value Stock Right Now?

    11:40 a.m. June 17, 2020

    - Zacks.com

  4. 7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains

    11:49 a.m. June 9, 2020

    - InvestorPlace.com

  5. Beware Anchoring Bias: Top Stocks Now

    2:52 a.m. June 2, 2020

    - Seeking Alpha

  6. Repligen (RGEN) Investor Presentation - Slideshow

    3:25 p.m. May 28, 2020

    - Seeking Alpha

  7. QGEN vs. RGEN: Which Stock Is the Better Value Option?

    11:40 a.m. May 28, 2020

    - Zacks.com

  8. Profit From 5 Stocks Likely to Beat on Earnings

    9:15 a.m. May 27, 2020

    - Zacks.com

  9. A Director at Repligen (RGEN) is Buying Shares

    2:01 a.m. May 27, 2020

    - SmarterAnalyst

  10. The CFO of Repligen (RGEN) is Selling Shares

    2:04 a.m. May 20, 2020

    - SmarterAnalyst

  11. Why Repligen (RGEN) Might be Well Poised for a Surge

    12:20 p.m. May 13, 2020

    - Zacks.com

  12. Winners Keep On Winning: Investing In Outperforming Stocks

    10:27 a.m. May 12, 2020

    - Seeking Alpha

  13. Repligen (RGEN) Received its Third Buy in a Row

    9:51 a.m. May 7, 2020

    - SmarterAnalyst

  14. Loading more headlines...

At a Glance

Repligen Corp.

41 Seyon Street

Building 1

Suite 100

Waltham, Massachusetts 02453

Phone

1 7812500111

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$270.25M

Net Income

$21.41M

2019 Sales Growth

39.3%

Employees

761.00

/news/pressrelease/company/us/rgen

Press Releases on RGEN

  1. Downstream Processing Market Will Exceed $42,754 Mn By 2026

    4:25 a.m. June 30, 2020

    - Global QYResearch

  2. Repligen Appoints Carrie Eglinton Manner to Board of Directors

    7:30 a.m. June 15, 2020

    - GlobeNewswire

  3. Repligen Appoints Carrie Eglinton Manner to Board of Directors

    7:30 a.m. June 15, 2020

    - GlobeNewswire

  4. Loading more headlines...
Link to MarketWatch's Slice.